Patents by Inventor Roger A. Poorman

Roger A. Poorman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140367278
    Abstract: A method for determining the level of survival motor neuron (SMN) protein in a whole blood or cerebral spinal fluid (CSF) sample, for example, a whole blood lysate sample or a CSF sample, including obtaining a whole blood or cerebral spinal fluid (CSF) sample from the subject and conducting an electrochemiluminescence immunoassay to determine the level of SMN in the whole blood or cerebral spinal fluid (CSF) sample.
    Type: Application
    Filed: June 11, 2014
    Publication date: December 18, 2014
    Applicant: PharmOptima, LLC
    Inventors: Phillip Zaworski, Roger Poorman, Douglas Decker
  • Publication number: 20040209283
    Abstract: The invention provides a method for detecting RNA polymerase activity in a continuous-read manner. Specifically, the invention provides a method for detecting the de novo polymerase activity of the Hepatitis C virus (HCV) polymerase, NS5B, in a continuous-read manner. The invention also provides a method of screening for modulators of RNA polymerase activity. More specifically, the invention provides a method of screening for modulators of HCV NS5B activity.
    Type: Application
    Filed: November 13, 2003
    Publication date: October 21, 2004
    Applicant: Pfizer Inc.
    Inventors: Yoshihiko Yagi, Michael P. Sheets, Peter A. Wells, John A. Shelly, Roger A. Poorman, Dennis E. Epps, Aric G. Morgan
  • Patent number: 6511813
    Abstract: Disclosed are novel methods of using elongation factor p (efp) and related constituents of ribosomal complexes which comprise efp, the 50S ribosomal subunit, the 30S ribosomal subunit, the 70S initiation complex, and related proteins, cofactors and enzymes. Methods of identifying compounds which modulate prokaryotic elongation factor p and modify cell function are described. Both in vitro and in vivo methods for identifying compounds which modulate such constituents and affect cell function are described. Such identified compounds, including various antibiotics, which specifically affect cell growth, methods of treating various disorders with such compounds, and antiseptics containing such compounds are described. The present invention is also directed to methods and compounds that modulate prokaryotic elongation factor p.
    Type: Grant
    Filed: November 2, 2000
    Date of Patent: January 28, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Keith R. Marotti, Roger A. Poorman, Peter A. Wells, Dean L. Shinabarger